
FLGT · NASDAQ
Fulgent Genetics, Inc.
$19.68 0.00 (0.00%)
Company overview
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests including Focus and Comprehensive oncology panel tests, Beacon carrier screening panels for inherited conditions, solid tumor molecular profiling for somatic cancer testing, rapid whole genome testing for children in NICU and PICU settings, newborn genetic analysis panels, single front-line tests to detect ataxia-related variants and repeat expansions through sequencing, patient-initiated picture genetics testing, whole exome and clinical exome panel tests, and whole genome, mutation, and repeat expansion testing services, as well as research service tests.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $542M
- Employees
- 1,313
- Headquarters
- El Monte, CA
- Website
- fulgentgenetics.com
- CEO
- Ming Hsieh
- Listed
- September 29, 2016
- P/E
- -8.27
- Dividend yield
- 0.00%
Company financials
- Revenue
- $320M
- Gross profit
- $124M
- Operating income
- -$106M
- EBITDA
- -$58.5M
- Net income
- -$73.8M
- EPS
- -$2.38
- Total assets
- $1.2B
- Total debt
- $10.2M
- Gross margin
- 38.71%
- Net margin
- -23.04%
- Earnings yield
- -12.09%
Showing FY 2025
News